Protective effect of dihydroheptaprenol in combination with vaccine to experimental Actinobacillus pleuropneumoniae infection in guinea pigs and pigs.
We investigated the effects of dihydroheptaprenol (DHP) on resistance of guinea pigs and pigs inoculated with Actinobacillus pleuropneumoniae (Apn) vaccine to subsequent challenge with Apn. Guinea pigs with complement-fixation (CF) antibody titers of 1:8 and 1:16 after intramuscular (i.m.) inoculation with inactivated Apn vaccine showed enhanced resistance to intraperitoneal (i.p.) infection with a homologous Apn strain (5 x 10(10) CFU/animal) when injected with DHP (20 mg/kg, i.m.) on the day before infection. The survival rates of the control, vehicle (lecithin solution without DHP), and DHP groups were 33%, 37%, and 63%, respectively, and that of the DHP group was significantly higher than the rates of the other groups (P < 0.05). Pigs with CF antibody titers of 1:8 and 1:16 after i.m. inoculation with inactivated Apn vaccine showed enhanced resistance to intratracheal infection with 5 x 10(10) CFU of Apn when injected with DHP (1, 2.5, or 5 mg/kg, i.m.) on the day before infection. The survival rates of the control, vehicle, DHP 1 mg/kg, DHP 2.5 mg/kg, and DHP 5 mg/kg groups were 37%, 38%, 47%, 60%, and 73%, respectively, and pigs given DHP at a dose of 5 mg/kg showed a significantly higher survival rate than the vaccinated control pigs (P < 0.05). The protective effect of DHP in vaccinated guinea pigs and pigs suggests that phagocytosis and bactericidal activity may be enhanced by this agent, depending on some opsonification effect on Apn antibody.
Animal Health Product Division, Eisai Co., Ltd., Tokyo, Japan.
M
M
Kimura
S
S
Araki
T
T
Nakai
K
K
Kume
D000189:Actinobacillus Infections / Q000517:prevention & control*; D016977:Actinobacillus pleuropneumoniae; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D003168:Complement Fixation Tests; D006168:Guinea Pigs; D007114:Immunization; D013552:Swine; D013729:Terpenes / Q000627:therapeutic use*
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D013729:Terpenes; C053452:dihydroheptaprenol